Research programme: mesenchymal stromal cell therapy - Orbsen Therapeutics

Drug Profile

Research programme: mesenchymal stromal cell therapy - Orbsen Therapeutics

Alternative Names: CD362+ stem cell therapy; CD362+SSC; Cyndacel-M; Cyndecel; ORB1+ MSC; ORB1+ SSC

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator Orbsen Therapeutics
  • Developer Orbsen Therapeutics; Regenerative Medicine Institute
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic foot ulcer
  • No development reported Adult respiratory distress syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in Ireland (IV)
  • 13 Apr 2016 Preclinical data presented at the International Liver Congress (ILC-2016)
  • 22 Apr 2014 Pharmacodynamics data from a preclinical study in Diabetic foot ulcer released by REDDSTAR
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top